A next-generation sequencing reference laboratory will use artificial intelligence (AI) to advance precision medicine to determine genomic signatures, first for cancer then other prevalent conditions. The goal of the tests is to offer diagnostic, prognostic, and predictive information about targeted options. The laboratory is a collaboration between Genomic Testing Cooperative (GTC) and Hackensack Meridian Health.
Maher Albitar, MD, chief executive officer, and chief medical officer at GTC said, “These laboratories will use the same algorithms and artificial intelligence approach in analyzing data with cross-validation, so the data can be grouped and used for developing new applications and new indications. This collaboration will allow GTC to co-develop new tests with HMH utilizing real-world clinical and outcomes data provided by HMH.”
More information here. (Source: Health IT Analytics, July 24, 2020).
